Bryan Murphy

Bryan Murphy

Auto-generated profile, based on publicly available information

Bryan Murphy

Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2012 in Cell Metabolism
Verified
Journal Article
Closed access
COChristine M. Oslowski
Christine M. Oslowski
THTakashi Hara
Takashi Hara
BOBryan O'Sullivan-Murphy
Bryan O'Sullivan-Murphy
KKKohsuke Kanekura
Kohsuke Kanekura
SLSimin Lu
Simin Lu
FUFumihiko Urano
Fumihiko Urano

1 April 2020 in Ultrasonography
Verified
Journal Article
Open access
PDF file
VMVenkatesh A. Murugan
Venkatesh A. Murugan
BMBryan O’sullivan Murphy
Bryan O’sullivan Murphy
CDCarolyn Dupuis
Carolyn Dupuis
AGAlan Goldstein
Alan Goldstein
YKYoung Kim
Young Kim
In patients presenting for an evaluation of pregnancy in the first trimester, transvaginal ultrasound is the modality of choice for establishing the presence of an intrauterine pregnancy; evaluating pregnancy viability, gestational age, and multiplicity; detecting pregnancy-related complications; and diagnosing ectopic pregnancy. In this pictorial review article, the sonographic appearance of a normal intrauterine gestation and the most common complications of pregnancy in the first trimester in the acute setting are discussed.

14 March 2012 in Diabetes
Verified
Journal Article
Open access
BOBryan O’sullivan-Murphy
Bryan O’sullivan-Murphy
FUFumihiko Urano
Fumihiko Urano

12 January 2012 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
IAIlya M. Alexandrov
Ilya M. Alexandrov
MIMaria Ivshina
Maria Ivshina
DJDae Young Jung
Dae Young Jung
RFRandall Friedline
Randall Friedline
HKHwi Jin Ko
Hwi Jin Ko
JRJoel D. Richter
Joel D. Richter
The cytoplasmic polyadenylation element binding protein CPEB1 (CPEB) regulates germ cell development, synaptic plasticity, and cellular senescence. A microarray analysis of mRNAs regulated by CPEB unexpectedly showed that several encoded proteins are involved in insulin signaling. An investigation of Cpeb1 knockout mice revealed that the expression of two particular negative regulators of insulin action, PTEN and Stat3, were aberrantly increased. Insulin signaling to Akt was attenuated in livers of CPEB–deficient mice, suggesting that they might be defective in regulating glucose homeostasis. Indeed, when the Cpeb1 knockout mice were fed a high-fat diet, their livers became insulin-resistant. Analysis of HepG2 cells, a human liver cell line, depleted of CPEB demonstrated that this protein directly regulates the translation of PTEN and Stat3 mRNAs. Our results show that CPEB regulated translation is a key process involved in insulin signaling. One major hallmark of diabetes is insulin resistance in peripheral tissues that is controlled at the posttranslational level. For example, insulin activates a kinase cascade that leads to the phosphorylation of Akt, a centrally important molecule that regulates glucose metabolism. In this study, we define a translational regulatory pathway that mediates insulin action in the liver. The Cytoplasmic Polyadenylation Binding Protein (CPEB) interacts with mRNA to control translation; knockout mice that lack CPEB exhibit high-fat-diet-induced liver insulin resistance and do so by having aberrant expression of major insulin signaling molecules, in particular PTEN 3 and Stat3. Our data further suggest that CPEB modulates, in a manner similar to a rheostat, functionally related mRNAs that encode proteins involved in insulin signaling.

1 April 2004 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
KDKonstantin H. Dragnev
Konstantin H. Dragnev
IPIan Pitha-Rowe
Ian Pitha-Rowe
YMYan Ma
Yan Ma
WPW. Jeffrey Petty
W. Jeffrey Petty
DSDavid Sekula
David Sekula
EDEthan Dmitrovsky
Ethan Dmitrovsky
Purpose: There is a need to identify cancer chemoprevention mechanisms. We reported previously that all-trans-retinoic acid (RA) prevented carcinogenic transformation of BEAS-2B immortalized human bronchial epithelial cells by causing G1 arrest, permitting repair of genomic DNA damage. G1 arrest was triggered by cyclin D1 proteolysis via ubiquitin-dependent degradation. This study investigated which chemopreventive agents activated this degradation program and whether cyclin E was also degraded. Experimental Design: This study examined whether: (a) cyclin E protein was affected by RA treatment; (b) cyclin degradation occurred in derived BEAS-2B-R1 cells that were partially resistant to RA; and (c) other candidate chemopreventive agents caused cyclin degradation. Results: RA treatment triggered degradation of cyclin E protein, and ALLN, a proteasomal inhibitor, inhibited this degradation. Induction of the retinoic acid receptor β, growth suppression, and cyclin degradation were each inhibited in BEAS-2B-R1 cells. Transfection experiments in BEAS-2B cells indicated that RA treatment repressed expression of wild-type cyclin D1 and cyclin E, but ALLN inhibited this degradation. Mutation of threonine 286 stabilized transfected cyclin D1, and mutations of threonines 62 and 380 stabilized transfected cyclin E, despite RA treatment. Specific chemopreventive agents triggered cyclin degradation. Nonclassical retinoids (fenretinide and retinoid X receptor agonists) and a synthetic triterpenoid (2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid) each suppressed BEAS-2B growth and activated this degradation program. However, a vitamin D3 analog (RO-24–5531), a cyclooxygenase inhibitor (indomethacin), and a peroxisome proliferator-activated receptor γ agonist (rosiglitazone) each suppressed BEAS-2B growth, but did not cause cyclin degradation. BEAS-2B-R1 cells remained responsive to nonclassical retinoids and to 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid. Conclusions: Specific chemopreventive agents activate cyclin proteolysis. Yet, broad resistance did not occur after acquired resistance to a single agent. This provides a therapeutic rationale for combination chemoprevention with agents activating non-cross-resistant pathways.

8 May 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SPSteven C. Pino
Steven C. Pino
BOBryan O'Sullivan-Murphy
Bryan O'Sullivan-Murphy
ELErich A. Lidstone
Erich A. Lidstone
CYChaoxing Yang
Chaoxing Yang
KLKathryn L. Lipson
Kathryn L. Lipson
RBRita Bortell
Rita Bortell
Gimap5 (GTPase of the immunity-associated protein 5) has been linked to the regulation of T cell survival, and polymorphisms in the human GIMAP5 gene associate with autoimmune disorders. The BioBreeding diabetes-prone (BBDP) rat has a mutation in the Gimap5 gene that leads to spontaneous apoptosis of peripheral T cells by an unknown mechanism. Because Gimap5 localizes to the endoplasmic reticulum (ER), we hypothesized that absence of functional Gimap5 protein initiates T cell death through disruptions in ER homeostasis. We observed increases in ER stress-associated chaperones in T cells but not thymocytes or B cells from Gimap5−/− BBDP rats. We then discovered that ER stress-induced apoptotic signaling through C/EBP-homologous protein (CHOP) occurs in Gimap5−/− T cells. Knockdown of CHOP by siRNA protected Gimap5−/− T cells from ER stress-induced apoptosis, thereby identifying a role for this cellular pathway in the T cell lymphopenia of the BBDP rat. These findings indicate a direct relationship between Gimap5 and the maintenance of ER homeostasis in the survival of T cells.